Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Other Non-Current Assets (2024 - 2025)

Xilio Therapeutics' Other Non-Current Assets history spans 2 years, with the latest figure at $1.8 million for Q3 2025.

  • For Q3 2025, Other Non-Current Assets rose 1.46% year-over-year to $1.8 million; the TTM value through Sep 2025 reached $1.8 million, up 1.46%, while the annual FY2024 figure was $1.8 million, N/A changed from the prior year.
  • Other Non-Current Assets for Q3 2025 was $1.8 million at Xilio Therapeutics, roughly flat from $1.8 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.8 million in Q3 2025 and bottomed at $92000.0 in Q2 2024.